Zimmer Partners LP Makes New Investment in Landos Biopharma, Inc. (NASDAQ:LABP)

Zimmer Partners LP acquired a new position in shares of Landos Biopharma, Inc. (NASDAQ:LABP) during the 1st quarter, Holdings Channel reports. The fund acquired 90,100 shares of the company’s stock, valued at approximately $868,000.

A number of other large investors also recently added to or reduced their stakes in LABP. Perceptive Advisors LLC bought a new position in shares of Landos Biopharma during the 1st quarter worth $159,688,000. RTW Investments LP purchased a new position in shares of Landos Biopharma in the first quarter worth about $38,328,000. Orbimed Advisors LLC purchased a new position in shares of Landos Biopharma in the first quarter worth about $6,558,000. Deerfield Management Company L.P. Series C purchased a new position in Landos Biopharma during the first quarter valued at approximately $4,334,000. Finally, JPMorgan Chase & Co. purchased a new position in Landos Biopharma during the first quarter valued at approximately $3,611,000. Institutional investors own 65.68% of the company’s stock.

LABP traded down $0.11 on Thursday, hitting $10.99. 34,247 shares of the company traded hands, compared to its average volume of 37,612. The stock’s 50 day moving average is $11.32. Landos Biopharma, Inc. has a 12-month low of $8.82 and a 12-month high of $16.99.

Landos Biopharma (NASDAQ:LABP) last released its quarterly earnings data on Sunday, May 16th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Analysts predict that Landos Biopharma, Inc. will post -1.44 earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered Landos Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Landos Biopharma presently has a consensus rating of “Buy” and an average price target of $22.60.

Landos Biopharma Profile

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases.

Featured Story: Commodities

Want to see what other hedge funds are holding LABP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Landos Biopharma, Inc. (NASDAQ:LABP).

Institutional Ownership by Quarter for Landos Biopharma (NASDAQ:LABP)

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.